Sofie Biosciences, Inc.

Sofie Biosciences, Inc. is a specialized manufacturer and supplier of molecular diagnostics and therapeutics, with a primary focus on radiopharmaceuticals and related services for the healthcare industry. The company provides a wide range of products and services to various federal agencies, including the Department of Veterans Affairs (VA), Defense Health Agency (DHA), and National Institutes of Health (NIH). Sofie Biosciences has extensive experience in positron emission tomography (PET) imaging and has been a key supplier of specialized imaging agents, prostate cancer detection tools, and injectable cancer drugs to VA hospitals, military treatment facilities, and federal research programs. The company's expertise in developing and delivering cutting-edge molecular imaging solutions has positioned it as a significant contributor to advancing diagnostic and therapeutic approaches in oncology and other medical fields.

Through federal contract awards, Sofie Biosciences has provided a variety of radiopharmaceuticals and related services. These include the supply of PET radiopharmaceuticals such as PYLARIFY (piflufolastat F-18), FDG (fluorodeoxyglucose), NEURACEQ (florbetaben F-18), and F-18 NaF for various VA medical centers and DHA facilities. The company has also delivered specialized imaging agents for prostate cancer detection, including PSMA-targeted radiotracers. Sofie has received numerous awards from the VA and DHA for the provision of these products, often through firm-fixed-price purchase orders or delivery orders against existing indefinite delivery vehicles. Many of these contracts have been awarded without set-aside designations, reflecting Sofie's established position as a specialized supplier in this field. The company's contracts have supported medical imaging and cancer treatment programs for veterans and military personnel across multiple healthcare facilities.

Regarding federal grant awards, Sofie Biosciences has participated as a sub-grantee in research projects funded by the National Institutes of Health. One notable example is a sub-award under a grant to Mayo Clinic for research on pancreatic ductal adenocarcinoma (PDA). In this project, Sofie is collaborating to develop and evaluate the use of 68Ga-FAP-Inhibitor (FAPI)-46 as a PET radiotracer for detecting and quantifying cancer-associated fibroblasts in PDA. This academic-industrial partnership aims to advance the clinical translation of this theranostic radiotracer, potentially impacting diagnostic and therapeutic approaches in oncology. The collaboration demonstrates Sofie's commitment to leveraging its expertise in radiopharmaceutical development to support cutting-edge research and innovation in molecular imaging.

Sofie Biosciences holds several significant Indefinite Delivery Vehicles (IDVs) with federal agencies, facilitating the ongoing procurement of its specialized products and services. These include multiple IDVs with the VA and DHA for the supply of radiopharmaceuticals, PET imaging agents, and related services. One notable IDV is valued at $5.86 million for PET radioactive isotopes and tracer supplies to the VA. Another IDV, worth $4.5 million, is specifically for PYLARIFY services and solutions to support the VA's prostate cancer programs. These IDVs allow for streamlined ordering processes, enabling VA medical centers, military treatment facilities, and other federal healthcare providers to efficiently procure Sofie's products for their imaging and treatment needs. The company's ability to secure and maintain these IDVs underscores its importance as a reliable supplier of critical radiopharmaceuticals and imaging solutions to the federal healthcare system.